Is early and fast blood pressure control important in hypertension management?

International Journal of Cardiology

Volumn 254, Issue , 2018, Pages 328-332

  Volpe, Massimo ^a,b   Gallo, Giovanna ^a   Tocci, Giuliano ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Cardiovascular prevention; Early blood pressure control; Hypertension; Prehyhpertension

Indexed keywords

AMLODIPINE; CANDESARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DISEASE MANAGEMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TIME FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; TIME FACTORS;

EID: 85038957635     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.12.026     Document Type: Article

References (55)

1. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J. Hypertens. 32 (2014), 2285–2295.
2. Ettehad, D., Emdin, C.A., Kiran, A., Anderson, S.G., Callender, T., Emberson, J., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
3. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 389 (2017), 37–55.
4. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
5. Redon, J., Mourad, J.J., Schmieder, R.E., Volpe, M., Weiss, T.W., Why in 2016 are patients with hypertension not 100% controlled? A call to action. J. Hypertens. 34 (2016), 1480–1488.
6. Tocci, G., Nati, G., Cricelli, C., Parretti, D., et al. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J. Hum. Hypertens. 31 (2017), 258–262.
7. Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G.T., Mitchell, L., Plat, F., Schork, A., Smith, B., Zanchetti, A., Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004), 2022–2031.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002), 2981–2997.
9. Dahlof, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, D.G., Caulfield, M., Collins, R., Kjeldsen, S.E., Kristinsson, A., McInnes, G.T., Mehlsen, J., Nieminen, M., O'Brien, E., Ostergren, J., Investigators, A.S.C.O.T., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 16:366 (2005), 895–906.
10. Trenkwalder, P., Elmfeldt, D., Hofman, A., Lithell, H., Olofsson, B., Papademetriou, V., et al. The study on cognition and prognosis in the elderly (SCOPE) — major CV events and stroke in subgroups of patients. Blood Press. 14 (2005), 31–37.
11. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., et al. Effects of a fixed combination of early control of blood pressure in high-risk patients perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
12. Chobian AV, Bakris GL, Black HR et al. and The National High Blood Pressure Education Program Coordinating Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289 (2003), 2560–2572.
13. James, P.A., Oparil, S., Carter, B.L., et al. 2014 evidence-based guidelines for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
14. National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. http://www.nice.org.uk/guidance/CG127.
15. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension, (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 34 (2013), 2159–2219.
16. Weber, M.A., Schiffrin, E.L., White, B., Mann, S., Lindholm, L., Kenerson, J.G., et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J. Hypertens. 32 (2014), 3–15.
17. The SPRINT Research Group, A randomized trial of intensive versus standard blood pressure contro. NEJM 373 (2015), 22–35.
18. Verdecchia, P., Reboldi, G., Angeli, F., Trimarco, B., Mancia, G., Pogue, J., Gao, P., Sleight, P., Teo, K., Yusuf, S., Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension 65 (2015), 108–114.
19. Xie, X., Atkins, E., Lv, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
20. Ettehad, D., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
21. Bundy, J.D., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality. A systematic review and network meta-analysis. JAMA Cardiol. 2:7 (2017), 775–781 Published online May 31.
22. Whelton, P.K., Carey, R.M., Aronow, W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J. Am. Coll. Cardiol., 2017, 10.1016/j.jacc.2017.11.006.
23. Vasan, R.S., Massaro, J.M., Wilson, P.W., Seshadri, S., Wolf, P.A., Levy, D., D'Agostino, R.B., Antecedent blood pressure and risk of cardiovascular disease: the Framingham heart study. Circulation 105 (2002), 48–53.
24. Bild, D.E., Bluemke, D.A., Burke, G.L., Detrano, R., Diez Roux, A.V., Folsom, A.R., Greenland, P., Jacob, D.R. Jr., Kronmal, R., Liu, K., Nelson, J.C., O'Leary, D., SaadMF, Shea S., Szklo, M., Tracy, R.P., Multi-ethnic study of atherosclerosis: objectives and design. Am. J. Epidemiol. 156 (2002), 871–881.
25. Howard, V.J., Cushman, M., Pulley, L., Gomez, C.R., Go, R.C., Prineas, R.J., Graham, A., Moy, C.S., Howard, G., The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 25 (2005), 135–143.
26. Loria, C.M., Liu, K., Lewis, C.E., et al. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA study. J Am CollCardiol. 49 (2007), 2013–2020.
27. Sundstrom, J., Arima, H., Jackson, R., et al. Blood pressure-lowering treatment Trialists’ collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann. Intern. Med. 162 (2015), 184–191.
28. Blood Pressure Lowering Treatment Trialists’ Collaboration. Predicted cardiovascular risk can inform decisions to lower blood pressure with drugs: evidence from an individual patient data meta-analysis. Lancet 384 (2014), 591–598.
29. Zanchetti, A., Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?. J. Hypertens. 27 (2009), 1509–1520.
30. Julius, S., et al. Feasibility of treating prehypertension with an angiotensin receptor blocker. N. Engl. J. Med. 354 (2006), 1685–1697.
31. Collins, D.R.J., Tompson, A.C., Onakpoya, I.J., Roberts, N., Ward, A.M., Henegham CJGlobal cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews. BMJ Open, 7, 2017, e013650.
32. Zhang, Y., et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample the Strong Heart Study. Hypertension 47 (2006), 410–414.
33. Thompson, A.M., Hu, T., Eshelbrenner, C.L., Reynolds, K., He, J., Bazzano, L.A., Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension. A meta-analysis. JAMA 305 (2011), 913–922.
34. Volpe, M., Erhardt, L.R.W., Williams, B., Managing cardiovascular risk: the need for change. J. Hum. Hypertens. 22 (2008), 154–157.
35. Neaton, J.D., Wentworth, D., Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple risk factor intervention trial research group. Arch. Intern. Med. 152 (1992), 56–64.
36. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 995–1003.
37. Jamerson, K., Weber, M.A., Bakris, G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359 (2008), 2417–2428.
38. Xu, W., Goldberg, S.I., Shubina, M., Turchia, A., Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ, 350, 2015, 158.
39. Wald, D.S., Law, M., Morris, J.K., Bestwick, J.P., Wald, N.J., Combination therapy versus monotherapy in reducing blood pressure meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122 (2009), 290–300.
40. Dresser, G.K., Nelson, S.A., Mahon, J.L., et al. Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2). J. Hypertens. 3 (2013), 1702–1713.
41. Brunner, H.R., et al. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assesed by 24-hour ambulatori blood pressure monitoring in patients with essential hypertension. Clin Drug Investig 23 (2003), 419–430.
42. Giles, T.D., Oparil, S., Silfani, T.N., et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 9 (2007), 187–195.
43. Oparil, S., Williams, D., Chrysant, S.G., Marbury, T.C., Neutel, J., Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. The. J. Clin. Hypertens. 3 (2001), 283–318.
44. Weir, M.R., et al. A randomized, double blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. Postgard Med 123 (2011), 80–87.
45. Redon, J., Fabia, M.J., Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. J. Renin-Angiotensin-Aldosterone Syst., 10(3), 2009.
46. Saito, et al. Early antihypertensive efficacy of olmesartan medoxomil. J. Clin. Hypertens. 10 (2008), 930–935.
47. Wang, L., Zhao, J.W., Liu, B., Shi, D., Zou, Z., Shi, X.Y., Antihypertensive effects ofolmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am. J. Cardiovasc. Drugs 12 (2012), 335–344.
48. Ram, C.V., Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J. Clin. Hypertens. 6 (2004), 569–577.
49. Volpe, M., Miele, C., Haag, U., Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig. 29 (2009), 381–391.
50. Chrysant, S.G., Izzo, J.L. Jr., Kereiakes, D.J., et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J. Am. Soc. Hypertens. 6:2 (2012), 132–141.
51. Nesbitt, S.D., et al. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP CRUSH study). J. Hum. Hypertens. 27 (2013), 445–452.
52. Bramlage, P., Fronk, E.M., Wolf, W.P., Smonlik, R., Sutton, G., Schmieder, R., Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. Vasc. Health Risk Manag. 11 (2015), 1–8.
53. Costa, F.V., Improving adherence to treatment and reducing economic costs of hypertension: the role of olmesartan based treatment. High Blood Press. Cardiovasc. Prev. 24 (2017), 265–274.
54. Volpe, M., de la Sierra, A., Kreutz, R., Laurent, S., Manolis, A., ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiov Prev. 21 (2014), 127–147.
55. Volpe, M., Tocci, G., de la Sierra, A., et al. Personalised single-pill combination therapy in hypertensive patients: an update of a practical treatment platform. High Blood Pressure and Cardiovascular Prevention, 24, 2017, 463–472.